{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:58:28Z","timestamp":1779004708208,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["T32-HL129964"],"award-info":[{"award-number":["T32-HL129964"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA248873"],"award-info":[{"award-number":["CA248873"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM108340-04"],"award-info":[{"award-number":["GM108340-04"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.exer.2021.108861","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T11:24:01Z","timestamp":1637580241000},"page":"108861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Inhibition of ocular neovascularization by novel anti-angiogenic compound"],"prefix":"10.1016","volume":"213","author":[{"given":"David","family":"Gau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucile","family":"Vignaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Francoeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-6614","authenticated-orcid":false,"given":"David","family":"Koes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-3935","authenticated-orcid":false,"given":"Xavier","family":"Guillonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-8531","authenticated-orcid":false,"given":"Partha","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2021.108861_bib1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in age-related macular degeneration: a review","volume":"12","author":"Al-Zamil","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.exer.2021.108861_bib2","doi-asserted-by":"crossref","first-page":"15636","DOI":"10.1074\/jbc.RA120.013963","article-title":"Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells","volume":"295","author":"Allen","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2021.108861_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICU.0000000000000657","article-title":"Age-related macular degeneration therapy: a review","volume":"31","author":"Ammar","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108861_bib4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2007.06.039","article-title":"Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients","volume":"144","author":"Brown","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108861_bib5","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1242\/jcs.03178","article-title":"Silencing profilin-1 inhibits endothelial cell proliferation, migration and cord morphogenesis","volume":"119","author":"Ding","year":"2006","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.exer.2021.108861_bib6","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.yexcr.2009.07.004","article-title":"Both actin and polyproline interactions of profilin-1 are required for migration, invasion and capillary morphogenesis of vascular endothelial cells","volume":"315","author":"Ding","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.exer.2021.108861_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10456-017-9560-y","article-title":"Pharmacological intervention of MKL\/SRF signaling by CCG-1423 impedes endothelial cell migration and angiogenesis","volume":"20","author":"Gau","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.exer.2021.108861_bib8","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1074\/jbc.RA120.012613","article-title":"Disruption of profilin1 function suppresses developmental and pathological retinal neovascularization","volume":"295","author":"Gau","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2021.108861_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/07853890600946724","article-title":"Age-related macular degeneration\u2013emerging pathogenetic and therapeutic concepts","volume":"38","author":"Gehrs","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.exer.2021.108861_bib10","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1159\/000373990","article-title":"Inhibition of ocular neovascularization by co-inhibition of VEGF-A and PLGF","volume":"35","author":"Huo","year":"2015","journal-title":"Cell. Physiol. Biochem. : Int. J. exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"10.1016\/j.exer.2021.108861_bib11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1096\/fj.201600351R","article-title":"Lebecetin, a C-type lectin, inhibits choroidal and retinal neovascularization","volume":"31","author":"Montassar","year":"2017","journal-title":"Faseb. J."},{"key":"10.1016\/j.exer.2021.108861_bib12","doi-asserted-by":"crossref","first-page":"108187","DOI":"10.1016\/j.exer.2020.108187","article-title":"Potential of subconjunctival aflibercept in treating choroidal neovascularization","volume":"199","author":"Nirmal","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2021.108861_bib13","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.2147\/DDDT.S219350","article-title":"Comparing the efficacy of an anti-human VEGF-A neutralizing antibody versus bevacizumab on A laser-induced choroidal neovascularization (CNV) rhesus monkey model","volume":"13","author":"Olvera-Monta\u00f1o","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.exer.2021.108861_bib14","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1167\/iovs.14-15067","article-title":"Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation","volume":"55","author":"Poor","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108861_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/c6b85ec4-996d-4daf-863a-44260a888470","article-title":"Choroid sprouting assay: an ex vivo model of microvascular angiogenesis","volume":"8","author":"Shao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2021.108861_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2147\/OPTH.S33372","article-title":"Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept","volume":"6","author":"Stewart","year":"2012","journal-title":"Clin. Ophthalmol."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:16:41Z","timestamp":1757999801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483521004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":16,"alternative-id":["S0014483521004279"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2021.108861","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of ocular neovascularization by novel anti-angiogenic compound","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2021.108861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108861"}}